Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PDE7A | Q13946 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24089986 | 0.91 | ALOX12 (0.55) | USP2RAB9ANPC1MAPTPDE7A | |
| SCHEMBL24090012 | 0.86 | TOP2A (0.60) | USP2RAB9ANPC1MAPTPDE7A | |
| SCHEMBL24090115 | 0.86 | ALDH1A1 (0.48) | USP2RAB9ANPC1MAPTPDE7A | |
| SCHEMBL29623296 | 0.86 | MAPT (0.43) | USP2MAPTPDE7A | |
| SCHEMBL29623172 | 0.86 | TDO2 (0.44) | POLB | |
| SCHEMBL23045330 | 0.86 | KDM4E (0.44) | KDM4E | |
| SCHEMBL24089963 | 0.86 | MAPT (0.43) | USP2MAPTPDE7A | |
| SCHEMBL24090107 | 0.86 | TDO2 (0.44) | POLB | |
| SCHEMBL29623225 | 0.86 | KDM4E (0.44) | KDM4E | |
| SCHEMBL24090135 | 0.85 | USP2 (0.48) | USP2RAB9ANPC1MAPTPDE7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352366-B2 | 2-aminoquinazolinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, CRKL | USP2 3443/4885RAB9A 1045/4885NPC1 1269/4885 |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, SLC26A3 | USP2 3548/4885RAB9A 902/4885NPC1 1276/4885 |
| US-11352366-B2 | 2-aminoquinazolinone derivative | CNKSR1, HAX1, SLC26A3 | USP2 3548/4885RAB9A 902/4885NPC1 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.